WEIGHT & METABOLIC RESEARCH
Studied for stronger, longer-lasting fullness after meals than GLP-1 compounds achieve on their own.
Cagrilintide is a long-acting mimic of amylin, the fullness hormone the pancreas releases alongside insulin. Phase 3 trials, including data on it used by itself, have reported promising weight-loss results, with stronger effects when it is combined with other compounds. It is positioned as a next-generation satiety compound and remains investigational.
Included because it has completed Phase 3 human trials and a clearly defined amylin-pathway mechanism, while its real-world research use is still developing. It reflects strong evidence that is not yet matched by an established use history.
Acts on amylin and calcitonin receptors in the brainstem and hypothalamus, the regions that register fullness, to reduce food intake.
Slows how fast the stomach empties so fullness lasts longer after a meal, and blunts the post-meal rise in glucagon.
Modeled as working synergistically with GLP-1 compounds for amplified appetite control.
WHAT THE RESEARCH MEASURED
Findings describe study outcomes, not expected personal results.
Cagrilintide is investigational and not FDA-approved. Phase 3 clinical data has been reported. Sold and offered strictly for laboratory and research use.
